NBIX vs. BMRN
NBIX (Neurocrine Biosciences, Inc.) and BMRN (BioMarin Pharmaceutical Inc.) are both stocks. Both are in the Healthcare sector — NBIX in Drug Manufacturers - Specialty & Generic, BMRN in Biotechnology. Over the past 10 years, NBIX returned 12.41%/yr vs -4.50%/yr for BMRN. At a 0.36 correlation, their price movements are largely independent.
Performance
NBIX vs. BMRN - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NBIX achieves a 17.99% return, which is significantly higher than BMRN's -4.98% return. Over the past 10 years, NBIX has outperformed BMRN with an annualized return of 12.41%, while BMRN has yielded a comparatively lower -4.50% annualized return.
NBIX
- 1D
- 1.36%
- 1M
- 23.91%
- YTD
- 17.99%
- 6M
- 8.51%
- 1Y
- 34.40%
- 3Y*
- 21.26%
- 5Y*
- 12.13%
- 10Y*
- 12.41%
BMRN
- 1D
- 3.31%
- 1M
- 6.07%
- YTD
- -4.98%
- 6M
- 4.92%
- 1Y
- 0.64%
- 3Y*
- -14.93%
- 5Y*
- -6.23%
- 10Y*
- -4.50%
NBIX vs. BMRN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NBIX Neurocrine Biosciences, Inc. | 17.99% | 3.90% | 3.60% | 10.31% | 40.24% | -11.14% | -10.83% | 50.53% | -7.96% | 100.49% |
BMRN BioMarin Pharmaceutical Inc. | -4.98% | -9.58% | -31.83% | -6.83% | 17.14% | 0.75% | 3.71% | -0.70% | -4.51% | 7.64% |
Correlation
The correlation between NBIX and BMRN is 0.42, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.42 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.36 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.39 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.43 |
Correlation (All Time) Calculated using the full available price history since Jul 27, 1999 | 0.36 |
Fundamentals
NBIX:
$17.30B
BMRN:
$11.16B
NBIX:
$6.53
BMRN:
$1.37
NBIX:
25.62
BMRN:
41.17
NBIX:
0.51
BMRN:
2.47
NBIX:
5.52
BMRN:
3.41
NBIX:
5.08
BMRN:
1.80
NBIX:
$3.10B
BMRN:
$3.24B
NBIX:
$3.05B
BMRN:
$2.46B
NBIX:
$881.20M
BMRN:
$439.56M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NBIX vs. BMRN — Risk / Return Rank
NBIX
BMRN
NBIX vs. BMRN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and BioMarin Pharmaceutical Inc. (BMRN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| NBIX | BMRN | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.09 | ||
| Sortino ratioReturn per unit of downside risk | +1.30 | ||
| Omega ratioGain probability vs. loss probability | 1.23 | 1.03 | +0.19 |
| Calmar ratioReturn relative to maximum drawdown | 1.65 | 0.03 | +1.62 |
| Martin ratioReturn relative to average drawdown | 3.64 | 0.06 | +3.58 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| NBIX | BMRN | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.11 | 0.02 | +1.09 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.37 | -0.19 | +0.56 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.32 | -0.13 | +0.44 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.15 | 0.11 | +0.03 |
Drawdowns
NBIX vs. BMRN - Drawdown Comparison
The maximum NBIX drawdown since its inception was -97.21%, which is greater than BMRN's maximum drawdown of -90.58%. Use the drawdown chart below to compare losses from any high point for NBIX and BMRN.
Loading charts...
Drawdown Indicators
| NBIX | BMRN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.21% | -90.58% | -6.63% |
Max Drawdown (1Y)Largest decline over 1 year | -20.90% | -22.49% | +1.59% |
Max Drawdown (3Y)Largest decline over 3 years | -42.89% | -49.83% | +6.94% |
Max Drawdown (5Y)Largest decline over 5 years | -42.89% | -57.64% | +14.75% |
Max Drawdown (10Y)Largest decline over 10 years | -46.39% | -62.09% | +15.70% |
Current DrawdownCurrent decline from peak | 0.00% | -62.13% | +62.13% |
Average DrawdownAverage peak-to-trough decline | -43.85% | -45.51% | +1.66% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.48% | 10.86% | -1.38% |
Volatility
NBIX vs. BMRN - Volatility Comparison
The current volatility for Neurocrine Biosciences, Inc. (NBIX) is 12.60%, while BioMarin Pharmaceutical Inc. (BMRN) has a volatility of 15.03%. This indicates that NBIX experiences smaller price fluctuations and is considered to be less risky than BMRN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NBIX | BMRN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.60% | 15.03% | -2.43% |
Volatility (6M)Calculated over the trailing 6-month period | 23.58% | 27.90% | -4.32% |
Volatility (1Y)Calculated over the trailing 1-year period | 31.10% | 34.72% | -3.62% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 32.73% | 32.90% | -0.17% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 39.19% | 35.52% | +3.67% |
Dividends
NBIX vs. BMRN - Dividend Comparison
Neither NBIX nor BMRN has paid dividends to shareholders.
Financials
NBIX vs. BMRN - Financials Comparison
This section allows you to compare key financial metrics between Neurocrine Biosciences, Inc. and BioMarin Pharmaceutical Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NBIX vs. BMRN - Profitability Comparison
NBIX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported a gross profit of 800.70M and revenue of 814.50M. Therefore, the gross margin over that period was 98.3%.
BMRN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, BioMarin Pharmaceutical Inc. reported a gross profit of 571.21M and revenue of 766.21M. Therefore, the gross margin over that period was 74.6%.
NBIX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported an operating income of 193.40M and revenue of 814.50M, resulting in an operating margin of 23.7%.
BMRN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, BioMarin Pharmaceutical Inc. reported an operating income of 129.64M and revenue of 766.21M, resulting in an operating margin of 16.9%.
NBIX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported a net income of 197.90M and revenue of 814.50M, resulting in a net margin of 24.3%.
BMRN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, BioMarin Pharmaceutical Inc. reported a net income of 105.53M and revenue of 766.21M, resulting in a net margin of 13.8%.
Frequently Asked Questions
NBIX and BMRN have a correlation of 0.42, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BMRN has higher volatility (15.03%) compared to NBIX (12.60%). In terms of maximum drawdown, NBIX dropped -97.21% vs BMRN's -90.58%.
NBIX currently has the higher Sharpe Ratio (1.11 vs 0.02), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NBIX and BMRN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer